CO2017010621A2 - Compuestos bicíclicos fusionados para el tratamiento de enfermedades - Google Patents
Compuestos bicíclicos fusionados para el tratamiento de enfermedadesInfo
- Publication number
- CO2017010621A2 CO2017010621A2 CONC2017/0010621A CO2017010621A CO2017010621A2 CO 2017010621 A2 CO2017010621 A2 CO 2017010621A2 CO 2017010621 A CO2017010621 A CO 2017010621A CO 2017010621 A2 CO2017010621 A2 CO 2017010621A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- treatment
- fused bicyclic
- bicyclic compounds
- compounds
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562138725P | 2015-03-26 | 2015-03-26 | |
| PCT/IB2016/000606 WO2016151403A1 (en) | 2015-03-26 | 2016-03-25 | Fused bicyclic compounds for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017010621A2 true CO2017010621A2 (es) | 2018-01-31 |
Family
ID=56072361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0010621A CO2017010621A2 (es) | 2015-03-26 | 2017-10-18 | Compuestos bicíclicos fusionados para el tratamiento de enfermedades |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10421759B2 (https=) |
| EP (2) | EP3715348A1 (https=) |
| JP (1) | JP6843061B2 (https=) |
| KR (1) | KR20180003545A (https=) |
| CN (1) | CN107912042A (https=) |
| AU (2) | AU2016238523A1 (https=) |
| BR (1) | BR112017020374A2 (https=) |
| CA (1) | CA2980394A1 (https=) |
| CL (1) | CL2017002405A1 (https=) |
| CO (1) | CO2017010621A2 (https=) |
| HK (1) | HK1249756A1 (https=) |
| IL (1) | IL254572A0 (https=) |
| MX (1) | MX370897B (https=) |
| RU (2) | RU2021107054A (https=) |
| SG (2) | SG10201908881PA (https=) |
| WO (1) | WO2016151403A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3715348A1 (en) * | 2015-03-26 | 2020-09-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| BR112018073460A2 (pt) * | 2016-05-25 | 2019-07-09 | Akarna Therapeutics Ltd | terapias combinadas usando moduladores do receptor farnesoide x (fxr) |
| KR20190040140A (ko) * | 2016-05-25 | 2019-04-17 | 아카나 테라퓨틱스, 엘티디. | 질환의 치료를 위한 융합된 비시클릭 화합물 |
| RU2019144064A (ru) * | 2017-06-02 | 2021-07-13 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения |
| CN108264474B (zh) * | 2018-02-09 | 2019-10-25 | 浙江师范大学 | 一种色胺及其衍生物的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595311B2 (en) * | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US8466143B2 (en) * | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| MX2007001539A (es) | 2004-08-10 | 2007-04-23 | Exelisis Inc | Compuestos heterociclicos como agentes farmaceuticos. |
| WO2006109633A1 (ja) | 2005-04-07 | 2006-10-19 | Daiichi Sankyo Company, Limited | 置換インドール化合物 |
| EP1963331A1 (en) | 2005-12-15 | 2008-09-03 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| US20090131409A1 (en) | 2007-10-22 | 2009-05-21 | Wyeth | 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| US20090137554A1 (en) * | 2007-10-22 | 2009-05-28 | Wyeth | 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY |
| CA2736880A1 (en) | 2008-09-26 | 2010-04-01 | Wyeth Llc | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| CN111662297A (zh) * | 2014-11-21 | 2020-09-15 | 阿卡纳治疗学有限公司 | 用于治疗疾病的稠合双环化合物 |
| WO2016103037A1 (en) * | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| EP3715348A1 (en) * | 2015-03-26 | 2020-09-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
-
2016
- 2016-03-25 EP EP20158977.7A patent/EP3715348A1/en not_active Withdrawn
- 2016-03-25 KR KR1020177030777A patent/KR20180003545A/ko not_active Ceased
- 2016-03-25 BR BR112017020374A patent/BR112017020374A2/pt not_active IP Right Cessation
- 2016-03-25 AU AU2016238523A patent/AU2016238523A1/en not_active Abandoned
- 2016-03-25 CA CA2980394A patent/CA2980394A1/en not_active Abandoned
- 2016-03-25 CN CN201680029952.3A patent/CN107912042A/zh active Pending
- 2016-03-25 HK HK18109050.8A patent/HK1249756A1/zh unknown
- 2016-03-25 SG SG10201908881P patent/SG10201908881PA/en unknown
- 2016-03-25 JP JP2017550113A patent/JP6843061B2/ja not_active Expired - Fee Related
- 2016-03-25 MX MX2017012342A patent/MX370897B/es active IP Right Grant
- 2016-03-25 WO PCT/IB2016/000606 patent/WO2016151403A1/en not_active Ceased
- 2016-03-25 EP EP16724699.0A patent/EP3274350A1/en not_active Withdrawn
- 2016-03-25 RU RU2021107054A patent/RU2021107054A/ru unknown
- 2016-03-25 SG SG11201707610PA patent/SG11201707610PA/en unknown
- 2016-03-25 RU RU2017137366A patent/RU2017137366A/ru unknown
-
2017
- 2017-09-18 IL IL254572A patent/IL254572A0/en unknown
- 2017-09-25 US US15/714,013 patent/US10421759B2/en active Active
- 2017-09-25 CL CL2017002405A patent/CL2017002405A1/es unknown
- 2017-10-18 CO CONC2017/0010621A patent/CO2017010621A2/es unknown
-
2019
- 2019-09-19 US US16/575,965 patent/US20200079782A1/en not_active Abandoned
-
2020
- 2020-10-12 AU AU2020256301A patent/AU2020256301A1/en not_active Abandoned
- 2020-11-17 US US17/099,864 patent/US20210214362A1/en not_active Abandoned
-
2022
- 2022-04-19 US US17/724,138 patent/US20230002394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL254572A0 (en) | 2017-11-30 |
| CA2980394A1 (en) | 2016-09-29 |
| US20230002394A1 (en) | 2023-01-05 |
| RU2017137366A3 (https=) | 2019-07-17 |
| RU2017137366A (ru) | 2019-04-26 |
| US20180118752A1 (en) | 2018-05-03 |
| WO2016151403A1 (en) | 2016-09-29 |
| RU2021107054A (ru) | 2021-03-31 |
| CL2017002405A1 (es) | 2018-04-27 |
| BR112017020374A2 (pt) | 2018-06-05 |
| SG11201707610PA (en) | 2017-10-30 |
| MX2017012342A (es) | 2018-06-11 |
| EP3274350A1 (en) | 2018-01-31 |
| JP6843061B2 (ja) | 2021-03-17 |
| MX370897B (es) | 2020-01-09 |
| CN107912042A (zh) | 2018-04-13 |
| US20200079782A1 (en) | 2020-03-12 |
| JP2018510876A (ja) | 2018-04-19 |
| AU2020256301A1 (en) | 2020-11-05 |
| AU2016238523A1 (en) | 2017-11-09 |
| US10421759B2 (en) | 2019-09-24 |
| SG10201908881PA (en) | 2019-11-28 |
| HK1249756A1 (zh) | 2018-11-09 |
| US20210214362A1 (en) | 2021-07-15 |
| KR20180003545A (ko) | 2018-01-09 |
| EP3715348A1 (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| MX2018003491A (es) | Represores de htt y usos de estos. | |
| CO2017004736A2 (es) | Péptidos macrociclicos útiles como inmunomoduladores | |
| CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| EA201691991A1 (ru) | Мультиспецифические антитела | |
| MX2017007049A (es) | Anticuerpos anti-cd79b y métodos de uso. | |
| MX389627B (es) | Inhibidores de la magl. | |
| AR101905A1 (es) | Compuestos bicíclicos | |
| MX2016010433A (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| LT3390390T (lt) | Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui | |
| CL2017002719A1 (es) | Imidazopirazinonas como inhibidores de pde1 | |
| MX2017002469A (es) | Composiciones de matrices extracelulares. | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| CO2018008249A2 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b | |
| DK3452465T3 (da) | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. | |
| MX2015009277A (es) | Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina. | |
| BR112017019176A2 (pt) | processos para a preparação de fluorocetolídeos | |
| MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |